Insulin Detemir: 6 agencies, 2004–2016
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused insulin detemir: all 13 decisive outcomes across 5 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 12.1 years separate the first record, 9 Aug 2004 at SMC (Scotland), from the most recent, 21 Sep 2016 at HAS (France).
PHARMAC (New Zealand) changed its position: restricted on 12 Nov 2009, recommended by 8 May 2014.
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for insulin detemir, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Nothing has been added since 2016; on this evidence the file is dormant.
5 distinct indication wordings are recorded for insulin detemir by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess insulin detemir, on 9 Aug 2004; AWMSG (Wales) did not open a file until 10 May 2012 — a wide spread of 7.8 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 9 years in total.
Restriction is doing real work here: 7 of 13 decisive outcomes narrowed insulin detemir to a subgroup rather than accepting or refusing it outright, at PHARMAC (New Zealand), SMC (Scotland) and TLV (Sweden).
6 of the 6 agencies here assessed insulin detemir more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for insulin detemir.
The full ledger for insulin detemir reads 7 restricted, 6 recommended, 3 other and 2 withdrawn, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 21 Sep 2016 | Indication extension | SMR substantial · ASMR V | source |
| SMC (Scotland) | 7 Mar 2016 | For treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. | accepted (restricted) | source |
| PHARMAC (New Zealand) | 8 May 2014 | Diabetes - type 1 (2nd-line LA insulin treatment) | PTAC advice: Cost Neutral | source |
| AWMSG (Wales) | 10 May 2012 | Treatment of diabetes mellitus in adults, adolescents and children as add-on therapy to liraglutide treatment | outside AWMSG criteria | source |
| TLV (Sweden) | 2 Dec 2009 | Vi beslutar att Levemir ska ingå i högkostnadsskyddet med begränsning | restricted subsidy | source |
14 further decisions for insulin detemir, across 6 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- insulin glargine — divergent outcome (restricted vs recommended) on a shared indication
- insulin glulisine — divergent outcome (restricted vs recommended) on a shared indication
- insulin aspart — same ATC class A10A — Diabetes
- insulin degludec — same ATC class A10A — Diabetes
- insulin lispro — same ATC class A10A — Diabetes
- insulin glargine / lixisenatide — same ATC class A10A — Diabetes
Coverage: 19 decisions for insulin detemir from 6 agencies, 2004 to 2016. Data to 7 Sep 2026. ATC class A10A — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.